School of Medicine
Showing 2,101-2,120 of 2,428 Results
-
Molly Tanenbaum
Clinical Associate Professor, Medicine - Endocrinology, Gerontology, & Metabolism
Clinical Associate Professor (By courtesy), Pediatrics - EndocrinologyBioDr. Tanenbaum is a clinical psychologist and clinical researcher committed to improving health and quality of life outcomes for people with diabetes. Dr. Tanenbaum’s research focuses on two main areas: 1) understanding and optimizing the role of technology (e.g. mobile technology/mHealth, diabetes devices, automated insulin delivery), and the feedback technology provides, to improve diabetes management; and 2) understanding the emotional experience of living with diabetes. Her recent work focused on developing a telehealth-based behavioral intervention for adults with type 1 diabetes to support adoption and sustained use of continuous glucose monitoring technology. She has expertise in using qualitative and mixed methods to take a human centered approach to understanding the context of living with and managing a chronic condition. Dr. Tanenbaum also has an interest in compassion-based approaches to addressing diabetes distress. As a licensed clinical psychologist, Dr. Tanenbaum provides consultation and behavioral medicine interventions with people living with diabetes.
-
Paul C Tang
Other Teaching Staff-Hourly, Medicine - Primary Care and Population Health
BioDr. Tang is Adjunct Professor in the Clinical Excellence Research Center at Stanford University and a practicing internist at the Palo Alto Medical Foundation. Most recently, he was Vice President, Chief Health Transformation Officer at IBM Watson Health. He has served in executive administration roles in health systems for over 25 years. Prior to joining Watson Health, Dr. Tang was Vice President, Chief Innovation and Technology Officer at the Palo Alto Medical Foundation (PAMF), directing the David Druker Center for Health Systems Innovation, a disruptive innovation center focused on grand challenges in health. Dr. Tang led one of the earliest implementations of an Electronic Health Record (EHR) system in the country in 1996, and in 2000, he co-developed MyChart, the first commercial patient portal, with Epic.
Dr. Tang is an elected member of the National Academy of Medicine, and has served on numerous NAM study committees, including a patient-safety committee he chaired that published two reports: Patient Safety: A New Standard for Care, and Key Capabilities of an Electronic Health Record System. He is a member of the Health and Medicine Division committee of the National Academies of Science, Engineering, and Medicine. Dr. Tang was co-chair of the federal Health Information Technology Policy committee from 2009-2017. He has served as board chair for several health informatics professional associations, including the American Medical Informatics Association (AMIA). He has served on the boards of AMIA, National Quality Forum, AcademyHealth, Computer-based Patient Record Institute, Joint Health Information Technology Alliance, NAM Board on Health Care Services, and National eHealth Collaborative. Dr. Tang is a recipient of the Nicholas E. Davies Award for Excellence in Computer-based Patient Record System Implementation, and the AMIA Don E. Detmer Award for Health Policy Contributions in Informatics. He currently holds one patent and has 16 patents pending. He has published numerous papers in medical informatics, appearing in New England Journal of Medicine, JAMA, Health Affairs, Annals of Internal Medicine, and Journal of the American Medical Informatics Association. Dr. Tang is a Fellow of the American College of Physicians, the American College of Medical Informatics, the College of Healthcare Information Management Executives, and the Healthcare Information and Management Systems Society.
He received his B.S. and M.S. in Electrical Engineering from Stanford University and his M.D. from the University of California, San Francisco. He completed his residency in internal medicine at Stanford University and is a board-certified practicing internist at the Palo Alto Medical Foundation. -
David Tehrani, MD, MS
Affiliate, Med/SHC Tri-Valley
BioDr. Tehrani is a board-certified, fellowship-trained interventional cardiologist with Stanford Health Care Tri-Valley in the East Bay.
He is focused on building long-term relationships with his patients and their families, while sharing his evidence-based expertise in the noninvasive and minimally invasive management of cardiovascular disease. He takes pride in forming care plans based on mutual decision-making.
Dr. Tehrani’s research interests include cutting-edge technology and advancements in medical management of cardiovascular disease. His clinical research studies and funded clinical research trials have focused on cardiovascular biomarkers, coronary physiology, cardiac hemodynamics, cardio-oncology, and procedural closure devices. His research background has been instrumental in helping him provide individualized, evidence-based care plans for conditions ranging from advanced heart failure to complex coronary disease.
Dr. Tehrani has an extensive clinical research background, with over 40 peer-reviewed publications in top cardiology journals. He has done over 30 presentations at conferences, including the American Heart Association (AHA) and American College of Cardiology (ACC) national meetings.
Dr. Tehrani is a member the American College of Cardiology, the American College of Physicians, the American Heart Association, the Heart Failure Society of America, and the International Society of Heart and Lung Transplantation. -
Melinda L. Telli, M.D.
Susy Yuan-Huey Hung Professor
Current Research and Scholarly InterestsMy research focuses on the development of novel therapies for the treatment of triple-negative and hereditary cancer. Other areas of interest include prevention of cardiac damage associated with breast cancer treatment and cardiotoxicity of anti-cancer agents.
-
Valerie Teng
Clinical Associate Professor, Medicine - Primary Care and Population Health
BioDr. Valerie Teng is a board certified family physician with special interests in preventative medicine and women's health. Her experiences in caring for patients with chronic conditions, such as diabetes and hypertension, have fueled her desire to partner with patients to enter healthier lifestyles. She is also passionate about providing comprehensive care to patients of all ages, including newborns and teens.
During her residency training, Dr. Teng explored many opportunities in medical education through the O’Connor-Stanford Leaders in Education Residency (OSLER) program. She is delighted to continue in medical education as a part of the faculty at Stanford Family Medicine. -
Stefano Testa, MD
Instructor, Medicine - Oncology
BioDr. Stefano Testa is a board-certified, fellowship-trained medical oncologist with Stanford Health Care. He is also a clinical instructor in the Department of Medicine, Division of Oncology at Stanford University School of Medicine.
Dr. Testa specializes in treating patients with sarcomas and other solid tumors using cellular therapy approaches. He has expertise in adoptive T-cell therapies, including chimeric antigen receptor T-cell (CAR-T) and T-cell receptor (TCR) therapies.
As a physician-scientist, Dr. Testa focuses on developing next-generation cellular therapies for solid tumors, particularly sarcomas. His research goal is to identify targets for adoptive T-cell therapies in solid tumors, including soft tissue and bone sarcomas, and on novel synthetic biology approaches to enhance the effectiveness of T-cell therapies against solid tumors.
Dr. Testa has authored numerous peer-reviewed publications in leading medical journals, including Immunity, Cancer Discovery, JAMA Network Open, Genome Medicine, and Biomacromolecules. He has presented his research at national and international scientific meetings, including the Connective Tissue Oncology Society Annual Meeting and the Society for Immunotherapy of Cancer Annual Meeting.
Dr. Testa is a member of the American Society of Clinical Oncology (ASCO), Connective Tissue Oncology Society (CTOS), the American Society of Hematology (ASH), and the Society for Immunotherapy of Cancer (SITC). -
Jeffrey Teuteberg
Professor of Medicine (Cardiovascular Medicine)
BioHe is currently a Professor of Medicine at Stanford, but is no longer seeing patients as he is on leave and working with industry.
His research interests are in clinical outcomes in patients after transplant and mechanical support as well as novel approaches to immunosuppression. He has participated in many single-center and multi-institutional research studies and has published widely in the fields of transplant and mechanical support. He served as President of the International Society of Heart and Lung Transplantation in 2018. -
Winifred Teuteberg
Clinical Professor, Medicine - Primary Care and Population Health
BioDr. Teuteberg completed residency training in Internal Medicine at the University of Chicago and a Palliative Medicine Fellowship at Massachusetts General Hospital. She joined the faculty at Stanford in 2017 and currently sees patients as a part of the inpatient palliative care consult team at Stanford Healthcare.
She has been the clinical director or Stanford Medicine's implementation of the Ariadne Labs' Serious Illness Care Program since its inception in 2018. Her interests include communication skills training, leveraging predictive algorithms to identify patients who would most benefit from serious illness conversations, how to empower non-physician clinical team members to participate in this work, and best practice for EHR builds related to advance care planning. -
Haluk Tezcan, MD
Adjunct Clinical Associate Professor, Medicine - Oncology
BioClinical focus:
Breast Oncology
Molecular Diagnostics
Dr. Tezcan is a medical oncologist and hematologist with over three decades of diverse experience in cancer management and research.
He is leading the clinical development of Droplet Biosciences' novel liquid biopsy technology, a first-in-class lymphatic fluid molecular residual disease assessment, overseeing the scientific and clinical development of the technology. With over three decades of direct patient care and clinical trial experience as a principal investigator and director, both in academia and private practice, he has a firsthand understanding of the unmet clinical needs of physicians and patients, as well as broad experience in clinical trial design and implementation.
He is also co-principal at Athea Oncology, guiding practices and hospitals in developing clinical trial programs and high-value real-world data collection and diagnostic companies in clinical development. He is also a reviewer of JCO Precision Medicine.
Before joining Athea Oncology and Droplet Biosciences, he was the co-founder of LexentBio, which was successfully acquired by Roche/FMI. He also served as Director of Translational Medicine at Genomic Health and as Vice President, leading oncology development at Counsyl, where he integrated science with clinical product development. He established the CA.RE.foundation, a cancer research foundation dedicated to enabling the execution of clinical trials across community oncology sites throughout the Northwest US. He has independently built multiple software tools to help oncologists navigate the practical realities of their daily work.
